Literature DB >> 26124057

Clinical utility of one versus two faecal immunochemical test samples in the detection of advanced colorectal neoplasia in symptomatic patients.

Josep Maria Auge, Callum G Fraser, Cristina Rodriguez, Alba Roset, Maria Lopez-Ceron, Jaume Grau, Antoni Castells, Wladimiro Jimenez.   

Abstract

BACKGROUND: The utility of faecal immunochemical tests (FIT) in assessment of symptomatic patients with lower gastrointestinal symptoms has not been well explored. The aims of this study were to evaluate the diagnostic yield for advanced colorectal neoplasia (ACRN) in symptomatic patients using the first of two FIT samples (FIT/1) and the higher concentration of two FIT samples (FIT/max).
METHODS: Samples from two consecutive bowel motions from 208 symptomatic patients who required colonoscopy were analysed using the HM-JACKarc analyser (Kyowa Medex Co., Ltd., Tokyo, Japan). Patients were categorised into two groups: patients with any ACRN and individuals with other diagnoses or normal colonoscopy.
RESULTS: Colonoscopy detected ACRN in 29 patients. In these patients, FIT/1 and FIT/max were significantly higher than in patients with low-risk adenoma (p=0.006 and p=0.024), other findings (p=0.002 and p=0.002) and normal colonoscopy (p<0.001 and p<0.001). The areas under the curves (AUC) of FIT/1 and FIT/max were 0.71 and 0.69, respectively. Undetectable FIT/1 rules out 96.6% of ACRN and the specificity was 10.6%. Increasing the FIT/1 cut-off to 10 μg Hb/g faeces, sensitivity and specificity were 34.5% and 87.2%, respectively. Similar results were obtained using FIT/max with 20 μg Hb/g faeces cut-off, providing a sensitivity and specificity of 34.5% and 85.6%, respectively.
CONCLUSIONS: Undetectable FIT is a good strategy to rule-out ACRN in symptomatic patients. The diagnostic yield of collecting two samples for FIT can be achieved with one sample, but a lower faecal haemoglobin concentrations (f-Hb) cut-off is required.

Entities:  

Mesh:

Year:  2016        PMID: 26124057     DOI: 10.1515/cclm-2015-0388

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  9 in total

1.  Is qFIT a useful tool in prioritising symptomatic patients referred with suspect colorectal cancer in the COVID-19 era?

Authors:  Sarah Small; Rachael Coulson; Robert Spence; Ian McAllister
Journal:  Ulster Med J       Date:  2022-06-15

2.  Faecal immunochemical tests for the diagnosis of symptomatic colorectal cancer in primary care: the benefit of more than one sample.

Authors:  Cecilia Högberg; Lars Söderström; Mikael Lilja
Journal:  Scand J Prim Health Care       Date:  2017-12       Impact factor: 2.581

3.  Impact of introducing a faecal immunochemical test (FIT) for haemoglobin into primary care on the outcome of patients with new bowel symptoms: a prospective cohort study.

Authors:  Craig Mowat; Jayne Digby; Judith A Strachan; Rebecca McCann; Christopher Hall; Duncan Heather; Francis Carey; Callum G Fraser; Robert J C Steele
Journal:  BMJ Open Gastroenterol       Date:  2019-05-04

4.  Accuracy of faecal immunochemical testing in patients with symptomatic colorectal cancer.

Authors:  A A Khan; M Klimovskij; R Harshen
Journal:  BJS Open       Date:  2020-09-18

5.  Diagnostic accuracy for colorectal cancer of a quantitative faecal immunochemical test in symptomatic primary care patients: a study protocol.

Authors:  Anna Lööv; Cecilia Högberg; Mikael Lilja; Elvar Theodorsson; Per Hellström; Alexandra Metsini; Louise Olsson
Journal:  Diagn Progn Res       Date:  2022-08-18

Review 6.  Faecal immunochemical tests (FIT) can help to rule out colorectal cancer in patients presenting in primary care with lower abdominal symptoms: a systematic review conducted to inform new NICE DG30 diagnostic guidance.

Authors:  Marie Westwood; Shona Lang; Nigel Armstrong; Sietze van Turenhout; Joaquín Cubiella; Lisa Stirk; Isaac Corro Ramos; Marianne Luyendijk; Remziye Zaim; Jos Kleijnen; Callum G Fraser
Journal:  BMC Med       Date:  2017-10-24       Impact factor: 8.775

7.  Is there an added value of faecal calprotectin and haemoglobin in the diagnostic work-up for primary care patients suspected of significant colorectal disease? A cross-sectional diagnostic study.

Authors:  Sjoerd G Elias; Liselotte Kok; Niek J de Wit; Ben J M Witteman; Jelle G Goedhard; Mariëlle J L Romberg-Camps; Jean W M Muris; Karel G M Moons
Journal:  BMC Med       Date:  2016-09-26       Impact factor: 8.775

8.  Symptom or faecal immunochemical test based referral criteria for colorectal cancer detection in symptomatic patients: a diagnostic tests study.

Authors:  Jesús-Miguel Herrero; Pablo Vega; María Salve; Luis Bujanda; Joaquín Cubiella
Journal:  BMC Gastroenterol       Date:  2018-10-25       Impact factor: 3.067

9.  Proton pump inhibitors reduce the accuracy of faecal immunochemical test for detecting advanced colorectal neoplasia in symptomatic patients.

Authors:  Lorena Rodriguez-Alonso; Francisco Rodriguez-Moranta; Claudia Arajol; Pau Gilabert; Katja Serra; Albert Martin; Gemma Ibáñez-Sanz; Victor Moreno; Jordi Guardiola
Journal:  PLoS One       Date:  2018-08-31       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.